Related Experiment Video
Updated: Jan 8, 2026
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.6K
Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβ.
Billy Michael Chelliah Jebaraj1, Stephan Stilgenbauer1
1Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany.
Blood Cancer Discovery
|December 12, 2025
Summary
Novel inhibitor MS-553 targets protein kinase PKCβ to overcome resistance in chronic lymphocytic leukemia (CLL) to BTK inhibitors. This approach induces apoptosis in resistant cells by blocking key signaling pathways.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Resistance to Bruton's tyrosine kinase (BTK) inhibitors is a significant clinical challenge in treating chronic lymphocytic leukemia (CLL).
- Identifying alternative therapeutic targets is crucial for managing refractory CLL cases.
Purpose of the Study:
- To investigate the efficacy of a novel protein kinase C beta (PKCβ) inhibitor, MS-553, in overcoming BTK inhibitor resistance in CLL.
- To elucidate the molecular mechanisms by which MS-553 exerts its anti-leukemic effects.
Main Methods:
- Utilized MS-553, a novel PKCβ inhibitor.
- Assessed the impact of MS-553 on B-cell receptor signaling, WNT/β-catenin, and NF-κB pathways.
- Evaluated apoptosis induction in BTK inhibitor-resistant CLL cells.
Main Results:
- MS-553 effectively inhibits PKCβ activity.
- Inhibition of PKCβ by MS-553 disrupts B-cell receptor signaling, WNT/β-catenin, and NF-κB pathways.
- MS-553 demonstrates potent apoptosis-inducing activity in CLL cells resistant to BTK inhibitors.
Conclusions:
- MS-553 represents a promising therapeutic strategy for overcoming BTK inhibitor resistance in chronic lymphocytic leukemia.
- Targeting PKCβ offers a viable approach to restore sensitivity to treatment in refractory CLL.
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K